Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 4 | 5 | 9 |
| 2008 | 3 | 14 | 17 |
| 2009 | 5 | 3 | 8 |
| 2010 | 7 | 11 | 18 |
| 2011 | 7 | 7 | 14 |
| 2012 | 8 | 7 | 15 |
| 2013 | 7 | 14 | 21 |
| 2014 | 18 | 8 | 26 |
| 2015 | 16 | 4 | 20 |
| 2016 | 19 | 12 | 31 |
| 2017 | 15 | 14 | 29 |
| 2018 | 22 | 6 | 28 |
| 2019 | 11 | 12 | 23 |
| 2020 | 13 | 11 | 24 |
| 2021 | 20 | 12 | 32 |
| 2022 | 2 | 17 | 19 |
| 2023 | 2 | 16 | 18 |
| 2024 | 13 | 5 | 18 |
| 2025 | 19 | 9 | 28 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case. Cancer Rep (Hoboken). 2026 Feb; 9(2):e70501.
-
Fyn-Saracatinib Complex Structure Reveals an Active State-like Conformation. Int J Mol Sci. 2026 Jan 23; 27(3).
-
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge. Nat Commun. 2026 Jan 14; 17(1):1726.
-
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. J Med Chem. 2026 Jan 22; 69(2):1119-1134.
-
Cutaneous Melanoma: A Review. JAMA. 2025 Dec 16; 334(23):2113-2125.
-
Design, synthesis, and biological evaluation of Benzimidazole-Aminopyrimidine hybrids as selective P38a MAPK inhibitors targeting Neuroinflammation in an AlCl3-induced rat model of Alzheimer's disease. Bioorg Chem. 2026 02; 169:109391.
-
CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them? Int J Mol Sci. 2025 Oct 23; 26(21).
-
Targeting the hepatic circadian clock concomitant with tyrosine kinase inhibition reverses late-stage hepatocellular carcinoma. Cell Rep. 2025 Nov 25; 44(11):116313.
-
COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale. Nat Commun. 2025 Sep 30; 16(1):8373.
-
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA. Cell Genom. 2025 Dec 10; 5(12):100987.